Skip to main content

Table 1 Changes in clinical characteristics for each study group based on basal insulin type among patients with type 2 diabetes

From: Clinical Characteristics of Withdrawal of Basal Insulin Therapy Among Japanese Patients with Type 2 Diabetes: A Multicenter Retrospective Observational Study

Patient characteristics Initiation of basal insulin
Deg Gla100 Gla300
Ma/e/female (n) 108/65 64/37 69/33
Insulin withdrawal within 6 months, n (male/female) 19/13 9/4 9/7
Age (years) 63.3 ± 12.7 63.7 ± 11.8 62.2 ± 14.3
Duration of diabetes (years) 8.7 ± 7.0*,** 11.8 ± 8.4 11.6 ± 9.9
SBP (mmHg) 130 ± 18 132 ± 18 135 ± 21
DBP (mmHg) 77 ± 10 76 ± 12 76 ± 14
Dose of basal insulin (U/day)
 First insulin dose 5.9 ± 1.9 (173)** 5.4 ± 1.5 (101) 5.2 ± 2.1 (102)
 At 1 month 7.2 ± 3.0 (169)**,‡ 7.2 ± 2.8 (100) 9.7 ± 5.2 (101)*,‡
 At 3 months 8.5 ± 4.6 (159)**,‡ 8.4 ± 3.8 (95) 11.8 ± 7.5 (95)*,‡
 At 6 months 10.4 ± 6.0 (141) 10.0 ± 5.8 (88) 12.5 ± 8.0 (86)
HbA1c (%)
 At start of study 10.03 ± 1.93 10.01 ± 2.21 10.29 ± 1.85
 At 1 month 9.05 ± 1.44**,‡ 8.95 ± 1.52 9.61 ± 1.60*,‡
 At 3 months 7.90 ± 1.29**,‡ 7.91 ± 1.39 8.47 ± 1.44*,‡
 At 6 months 7.65 ± 1.31 7.75 ± 1.31 7.92 ± 1.51
HbA1c (mmol/mol)
 At start of study 86.08 ± 21.04 85.96 ± 24.18 88.97 ± 20.27
 At 1 month 75.44 ± 15.72**,‡ 74.37 ± 16.65 81.56 ± 17.46*,‡
 At 3 months 62.80 ± 14.08**,‡ 62.99 ± 15.25 69.12 ± 15.76*,‡
 At 6 monthn 60.10 ± 14.36 61.18 ± 14.28 63.02 ± 16.45
BMI (kg/m2)
 At start of study 25.3 ± 4.4 25.2 ± 4.7 25.3 ± 4.8
 At 1 month 25.4 ± 4.4 25.3 ± 4.6 25.1 ± 4.6
 At 3 months 25.2 ± 4.5 25.4 ± 4.5 25.2 ± 4.4
 At 6 months 25.4 ± 4.5† 25.8 ± 4.7 25.2 ± 4.4
Treatment of diabetes with glimepiride, gliclazide, and glibenclamide, n (dosage in mg))
 At start of study 25 (1.04 ± 0.71)/5 (28.0 ± 11.0)/1 (2.5) 42 (1.47 ± 0.88)/8 (35.0 ± 20.0)/1 (2.5) 22 (1.38 ± 0.82)/4 (20.0 ± 0.0)/6 (1.67 ± 0.65)
 At 6 months 21 (0.79 ± 0.48)/7 (21.4 ± 13.5)/0 33 (1.12 ± 0.87)/9 (21.1 ± 14.5)/0 22 (0.77 ± 0.49)/5 (16.0 ± 5.5)/4 (0.96 ± 0.33)
Treatment of diabetes with rapid-acting insulin/SGLT2I/GLP-1RA/TZD (n)
 At start of study 0/53/0/8 0/7/0/10 0/23/0/13
 At 6 months 11/67/7/6 10/12/2/11 3/34/2/12
Treatment of diabetes with glinide/BG/α-GI/DPP-4I (n)
 At start of study 33/52/46/144 6/33/21/89 12/35/22/84
 At 6 months 41/70/53/149 10/40/24/88 16/40/24/82
  1. Data are shown as mean ± standard deviation (SD) unless indicated otherwise
  2. Deg Insulin degludec 100 U/mL, Gla100 insulin glargine 100 U/mL, Gla300 insulin glargine 300 U/mL, SBP systolic blood pressure, DBP diastolic blood pressure, HbA1c glycated hemoglobin, BMI body mass index, SGLT2I sodium-glucose co-transporter 2 inhibitors, GLP-1RA glucagon-like peptide 1 receptor agonist, TZD thiazolidinedione, BG biguanide, α-GI alpha-glucosidase inhibitors, DPP-4I dipeptidyl peptidase-4 inhibitors
  3. *Significant at P < 0.05 compared with insulin glargine U 100/mL (Gla100) after adjustment for age and gender. **Significant at P < 0.05 compared with Gla300 after adjustment for age and gender. Signficant at P < 0.05 compared with data at start of study. Significant at P < 0.01 compared with data at start of study